SMT202100007T1 - Ligandi modificati mediante permutazione circolare come agonisti e antagonisti - Google Patents

Ligandi modificati mediante permutazione circolare come agonisti e antagonisti

Info

Publication number
SMT202100007T1
SMT202100007T1 SM20210007T SMT202100007T SMT202100007T1 SM T202100007 T1 SMT202100007 T1 SM T202100007T1 SM 20210007 T SM20210007 T SM 20210007T SM T202100007 T SMT202100007 T SM T202100007T SM T202100007 T1 SMT202100007 T1 SM T202100007T1
Authority
SM
San Marino
Prior art keywords
agonists
antagonists
circular permutation
ligands modified
ligands
Prior art date
Application number
SM20210007T
Other languages
English (en)
Inventor
Juan Alvarez
Jean Chamoun
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of SMT202100007T1 publication Critical patent/SMT202100007T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
SM20210007T 2012-06-08 2013-06-06 Ligandi modificati mediante permutazione circolare come agonisti e antagonisti SMT202100007T1 (it)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261657378P 2012-06-08 2012-06-08
US201261657285P 2012-06-08 2012-06-08
US201261657264P 2012-06-08 2012-06-08
US201261723081P 2012-11-06 2012-11-06
US201361778812P 2013-03-13 2013-03-13
US201361778575P 2013-03-13 2013-03-13
EP18162555.9A EP3401402B1 (en) 2012-06-08 2013-06-06 Ligands modified by circular permutation as agonists and antagonists

Publications (1)

Publication Number Publication Date
SMT202100007T1 true SMT202100007T1 (it) 2021-03-15

Family

ID=49712642

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20180363T SMT201800363T1 (it) 2012-06-08 2013-06-06 Ligandi modificati mediante permutazione circolare come agonisti e antagonisti
SM20210007T SMT202100007T1 (it) 2012-06-08 2013-06-06 Ligandi modificati mediante permutazione circolare come agonisti e antagonisti

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20180363T SMT201800363T1 (it) 2012-06-08 2013-06-06 Ligandi modificati mediante permutazione circolare come agonisti e antagonisti

Country Status (20)

Country Link
US (8) US9359415B2 (it)
EP (5) EP2859015B1 (it)
JP (7) JP6234446B2 (it)
AU (3) AU2013271542B2 (it)
CA (3) CA2869786A1 (it)
CY (2) CY1120522T1 (it)
DK (2) DK2859015T3 (it)
ES (4) ES2842677T3 (it)
HR (2) HRP20180914T1 (it)
HU (2) HUE052908T2 (it)
LT (2) LT2859015T (it)
ME (1) ME03079B (it)
NZ (4) NZ630849A (it)
PL (2) PL2859015T3 (it)
PT (2) PT2859015T (it)
RS (2) RS57369B1 (it)
SI (2) SI2859015T1 (it)
SM (2) SMT201800363T1 (it)
TR (2) TR201809046T4 (it)
WO (3) WO2013184939A2 (it)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2859015T3 (en) * 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
MA40094B1 (fr) * 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
US11938193B2 (en) 2016-01-08 2024-03-26 Washington University Compositions comprising chemerin and methods of use thereof
CA3026393C (en) * 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
EP3481412A4 (en) 2016-07-11 2020-03-18 The National Institute for Biotechnology in the Negev, Ltd. FUSION PROTEINS WITH EXTENDED SERUM HALF-VALUE
EP3600429B1 (en) * 2017-03-20 2023-10-25 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
KR101784288B1 (ko) * 2017-04-26 2017-10-11 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 열 충격 단백질 10의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
KR101800200B1 (ko) 2017-05-26 2017-11-23 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 성장 분화 인자 11과 상피세포 성장인자의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물
CN117737045A (zh) 2017-06-27 2024-03-22 科德克希思公司 青霉素g酰化酶
CN107362351B (zh) * 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
AU2018390418B2 (en) 2017-12-19 2023-12-21 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2019143193A1 (ko) 2018-01-19 2019-07-25 주식회사 펩진 재조합 폴리펩타이드 생산용 n-말단 융합 파트너 및 이를 이용하여 재조합 폴리 펩타이드를 생산하는방법
KR102824112B1 (ko) * 2018-03-28 2025-06-24 브리스톨-마이어스 스큅 컴퍼니 인터루킨-2/인터루킨-2 수용체 알파 융합 단백질 및 사용 방법
EP3792276A4 (en) * 2018-04-26 2022-02-16 Good T Cells, Inc. NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF
CN108948178A (zh) * 2018-07-20 2018-12-07 安他杰（杭州）生物医药科技有限公司 一种改良的人il-37蛋白及其应用
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
JP7355326B2 (ja) * 2019-08-05 2023-10-03 デンカ株式会社 経粘膜投与薬剤
EP4045077A1 (en) 2019-10-18 2022-08-24 Alkermes Pharma Ireland Limited Immunomodulatory il-2 agents in combination with immune checkpoint inhibitors
AU2020394444B2 (en) 2019-11-25 2025-05-29 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
CN116925237A (zh) * 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
JP2023511946A (ja) * 2020-01-24 2023-03-23 アルカームス ファーマ アイルランド リミテッド 精製方法
EP3946612A4 (en) * 2020-03-21 2024-11-20 Larix Biosciences LLC BISPECIFIC AND TRISPECIFIC FUNCTIONAL MOLECULES OF ACE2 AND COMPLEMENT PATHWAYS AND THEIR USE
AU2021254793A1 (en) * 2020-04-15 2022-11-17 Clovis Oncology, Inc. Immunostimulatory agents in combination with angiogenesis inhibitors
WO2021211857A1 (en) 2020-04-15 2021-10-21 Alkermes Pharma Ireland Limited Immunostimulatory agents in combination with angiogenesis inhibitors
JP2023524639A (ja) 2020-04-22 2023-06-13 アイオバンス バイオセラピューティクス，インコーポレイテッド 患者特異的免疫療法用細胞の製造調整システム及び調整方法
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CN115867307A (zh) * 2020-05-11 2023-03-28 奥克梅斯制药爱尔兰有限公司 Il-2融合多肽组合物以及其制备和使用方法
CA3172871A1 (en) * 2020-05-11 2021-11-18 Francisca O. GBORMITTAH Il-2 fusion polypeptide compositions and methods of making and using the same
CN111662973B (zh) * 2020-05-28 2023-08-25 广州医科大学附属第一医院（广州呼吸中心） 与慢性阻塞性肺疾病易感性辅助诊断相关的snp位点及其应用
US20230322882A1 (en) * 2020-07-08 2023-10-12 Nanjing Normal University Fusion Polypeptide and Polypeptide Dimer, and Use Thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
JP2023536100A (ja) * 2020-07-27 2023-08-23 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
WO2022099695A1 (en) * 2020-11-16 2022-05-19 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Cd164 fusion and uses thereof
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
CA3201818A1 (en) 2020-12-11 2022-06-16 Maria Fardis Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CA3203382A1 (en) 2020-12-31 2022-07-07 Adrian Emanual Wells Devices and processes for automated production of tumor infiltrating lymphocytes
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
JP2024510505A (ja) 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
EP4314073A4 (en) 2021-03-24 2025-02-19 Alkermes, Inc. Upar antibodies and fusion proteins with the same
WO2022204564A2 (en) 2021-03-25 2022-09-29 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
JP2024511465A (ja) 2021-03-26 2024-03-13 イナート・ファルマ・ソシエテ・アノニム Ｎｋ細胞エンゲージングのためにサイトカインに融合したｎｋｐ４６結合性部位、がん抗原結合性部位を含む多特異性タンパク質
KR20240037185A (ko) 2021-04-19 2024-03-21 이오반스 바이오테라퓨틱스, 인크. 키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
MX2023014647A (es) 2021-06-09 2024-01-31 Innate Pharma Proteinas de union a nkp46 multiespecificas.
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
CA3232700A1 (en) 2021-09-24 2023-03-30 Rafael CUBAS Expansion processes and agents for tumor infiltrating lymphocytes
CA3235824A1 (en) 2021-10-27 2023-05-04 Frederick G. Vogt Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US20250032618A1 (en) 2021-11-10 2025-01-30 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
US20250101380A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CA3247638A1 (en) 2022-04-06 2023-10-12 Maria Fardis TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
KR102798377B1 (ko) * 2022-04-26 2025-04-22 전남대학교산학협력단 원형순열에 기반한 기능성 재조합 인간 섬유아세포 성장인자 7의 제조방법 및 그 용도
US20250281537A1 (en) 2022-05-10 2025-09-11 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
WO2023235790A1 (en) * 2022-06-01 2023-12-07 University Of Miami Bifunctional il-2 and il-10 fusion proteins and uses thereof
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
CN117003852B (zh) * 2022-07-07 2024-11-05 北京大学 白细胞介素-2的拓扑改造及其作为自身免疫病药物的应用
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2025531877A (ja) 2022-09-09 2025-09-25 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
CN117106024B (zh) * 2022-10-21 2024-05-24 南京市妇幼保健院 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
KR20250122544A (ko) 2022-11-21 2025-08-13 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
AU2023408619A1 (en) * 2022-12-22 2025-07-10 Anaveon AG Il-2 fusion protein
EP4431525A1 (en) 2023-03-16 2024-09-18 Anaveon AG Il-2 fusion protein
EP4562059A1 (en) * 2023-02-21 2025-06-04 RemeGen Co., Ltd. Il-15 agonists for cancer
EP4743565A2 (en) 2023-07-13 2026-05-20 Iovance Biotherapeutics Inc Lentiviral vectors encoding cytokines and their uses in the production of tumor-infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
IL325654A (en) * 2023-07-25 2026-02-01 Zahav Bioscience Llc Cytokine compounds and methods of using them
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
US20250243279A1 (en) 2023-10-17 2025-07-31 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026072794A2 (en) 2024-09-26 2026-04-02 Iovance Biotherapeutics, Inc. Expansion processes for til product enriched with neoantigen- reactive t cells (narts)

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5872095A (en) 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
US5747444A (en) 1990-10-09 1998-05-05 Chiron Corporation Method of treating graft-versus-host disease
US5635599A (en) * 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5837495A (en) 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
IT1270662B (it) 1994-10-13 1997-05-07 Applied Research Systems Antagonista della interleuchina-1
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
DE69725747T2 (de) 1996-08-23 2004-07-29 Sequus Pharmaceuticals, Inc., Menlo Park Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
AU4907897A (en) 1996-10-11 1998-05-11 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
PL189756B1 (pl) 1996-10-25 2005-09-30 Searle & Co Polipeptyd ludzkiego agonisty receptora erytropoetyny (EPO), sposób jego wytwarzania i zastosowanie, cząsteczka kwasu nukleinowego, kompozycja, sposób selektywnego namnażania ex vivo erytroidalnych komórek progenitorowych
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
JP2002526380A (ja) 1997-10-31 2002-08-20 バイオミラ，インコーポレイテッド 癌関連ｍｕｃ−１ムチン誘発免疫抑制の治療におけるｍｕｃ−１誘導体とその使用法
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US6492492B1 (en) 1998-04-03 2002-12-10 University Of Washington Circularly permuted biotin binding proteins
SI1180378T1 (sl) 1999-03-03 2011-04-29 Optinose As Nazalni aplikator
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP1248840A2 (en) 2000-01-13 2002-10-16 Panorama Research, Inc. Circularly permutated, interaction-activated proteins
US6497870B1 (en) 2000-05-22 2002-12-24 Hyseq, Inc. Therapeutic uses of il-1 receptor antagonist
US7446183B2 (en) 2000-06-16 2008-11-04 Asterion Limited Fusion protein comprising growth hormone and growth hormone receptor
IL154777A0 (en) 2000-09-14 2003-10-31 Applied Research Systems Il-6 receptor/il-6 chimera in huntington's disease
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
JP2004519230A (ja) 2001-02-06 2004-07-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたインターロイキン−１受容体アンタゴニスト（ｉｌ−１ｒａ）
JP4421894B2 (ja) 2001-07-20 2010-02-24 アブソーバー アクチボラゲット 血液型抗原融合ポリペプチドおよびその使用方法
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
IL147412A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration
AU2003222415B2 (en) * 2002-04-18 2009-02-05 Yeda Research And Development Co. Ltd. Derivatives of the IL-2 receptor gamma chain, their production and use
AU2003228067B2 (en) 2002-04-22 2008-05-29 Recopharma Ab Mucin fusion polypeptide vaccines, compositions and methods of use thereof
US20080241166A1 (en) 2002-06-28 2008-10-02 Domantis Limited Ligands that bind a receptor
EP1534748A2 (en) 2002-08-09 2005-06-01 Recopharma AB Fusion proteins and methods of producing same
US20040175359A1 (en) 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
GB0315182D0 (en) 2003-06-28 2003-08-06 Asterion Ltd Cytokine variant polypeptides
WO2005034863A2 (en) * 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) * 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
US8338138B2 (en) 2004-01-28 2012-12-25 The John Hopkins University Methods for making and using molecular switches involving circular permutation
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
EP1781684A4 (en) 2004-08-25 2008-05-21 Amprotein Corp NEW CHIMERE POLYPEPTIDE AND USE THEREOF
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
WO2006086607A2 (en) 2005-02-10 2006-08-17 Emory University Novel proteins with enhanced functionality and methods of making novel proteins using circular permutation
CA2618791C (en) * 2005-08-12 2014-05-13 Riken Novel mucin-type glycoprotein and use thereof
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20100016547A1 (en) * 2005-11-30 2010-01-21 Takaomi Ito Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient
DE602005015733D1 (de) * 2005-12-02 2009-09-10 Apceth Gmbh & Co Kg Chemokin-Mucin Fusionsproteine mit einer GPI-Ankerdomäne und deren Verwendung als Tumor-Immun-Adjuvanzien oder in der Geweberegeneration
GB0606946D0 (en) 2006-04-06 2006-05-17 Asterion Ltd Polypeptide antagonist
US20100063258A1 (en) 2006-06-28 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Fusion protein constructs
ES2535358T3 (es) 2006-12-12 2015-05-08 Biorexis Pharmaceutical Corporation Bibliotecas de proteínas de fusión de transferrina
US8618324B2 (en) 2007-03-13 2013-12-31 Board Of Regents, The University Of Texas System Composition and method for making oligo-benzamide compounds
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
CA2691785C (en) * 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
MX2010001684A (es) * 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
DE102007049830A1 (de) 2007-10-16 2009-04-23 Henkel Ag & Co. Kgaa Neue Proteinvarianten durch zirkulare Permutation
EP2050759A1 (en) 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
AU2009256457B2 (en) * 2008-05-29 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Cell line, system and method for optical control of secondary messengers
JP5604297B2 (ja) * 2008-06-17 2014-10-08 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
CN108530543B (zh) * 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP3165606A1 (en) * 2009-05-01 2017-05-10 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
EP2553101A4 (en) 2010-04-02 2013-09-04 Univ Rochester PROTEASE-ACTIVATED CYTOKINES
US9119869B2 (en) 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
SG187231A1 (en) * 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
EP2619229B1 (en) * 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US9511151B2 (en) * 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
WO2013170636A1 (zh) * 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
DK2859015T3 (en) * 2012-06-08 2018-06-18 Alkermes Inc LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS

Also Published As

Publication number Publication date
US10023623B2 (en) 2018-07-17
JP7048543B2 (ja) 2022-04-05
NZ715099A (en) 2018-12-21
US20130336924A1 (en) 2013-12-19
AU2013271541B2 (en) 2016-03-17
US20140234962A1 (en) 2014-08-21
NZ630849A (en) 2016-04-29
RS57369B1 (sr) 2018-08-31
JP2015520193A (ja) 2015-07-16
EP3401402B1 (en) 2020-10-14
CY1120522T1 (el) 2019-07-10
EP3825405A1 (en) 2021-05-26
EP2859015B1 (en) 2018-03-21
LT3401402T (lt) 2020-12-28
RS61391B1 (sr) 2021-02-26
TR201809046T4 (tr) 2018-07-23
CA2869674A1 (en) 2013-12-12
WO2013184939A2 (en) 2013-12-12
US20160052983A1 (en) 2016-02-25
EP2859015A1 (en) 2015-04-15
HK1210055A1 (en) 2016-04-15
HRP20201973T1 (hr) 2021-02-05
US10183979B2 (en) 2019-01-22
EP2859015A4 (en) 2015-11-18
CA2869787A1 (en) 2013-12-12
SMT201800363T1 (it) 2018-09-13
HK1203969A1 (en) 2015-11-06
HUE037849T2 (hu) 2018-09-28
JP2022050391A (ja) 2022-03-30
NZ630848A (en) 2016-07-29
ES2667558T3 (es) 2018-05-11
JP2018038389A (ja) 2018-03-15
JP6388408B2 (ja) 2018-09-12
JP7350041B2 (ja) 2023-09-25
JP2015525216A (ja) 2015-09-03
US20130336925A1 (en) 2013-12-19
TR201808753T4 (tr) 2018-07-23
US9296801B2 (en) 2016-03-29
US20130338067A1 (en) 2013-12-19
EP2858672A4 (en) 2016-02-10
ME03079B (me) 2019-01-20
US20200040053A1 (en) 2020-02-06
NZ630851A (en) 2016-07-29
EP3401402A1 (en) 2018-11-14
ES2675784T3 (es) 2018-07-12
HK1203820A1 (en) 2015-11-06
US20160237132A1 (en) 2016-08-18
CY1124525T1 (el) 2022-07-22
DK3401402T3 (da) 2021-01-11
PT2859015T (pt) 2018-06-26
DK2859015T3 (en) 2018-06-18
CA2869787C (en) 2021-11-23
JP2019195332A (ja) 2019-11-14
AU2013271542A1 (en) 2014-10-16
HUE052908T2 (hu) 2021-05-28
JP2015525217A (ja) 2015-09-03
JP2023109948A (ja) 2023-08-08
PL3401402T3 (pl) 2021-05-31
JP6545759B2 (ja) 2019-07-17
ES2675568T3 (es) 2018-07-11
WO2013184939A3 (en) 2014-01-30
HRP20180914T1 (hr) 2018-07-27
US10407481B2 (en) 2019-09-10
AU2013271545B2 (en) 2016-03-03
SI3401402T1 (sl) 2021-03-31
AU2013271542B2 (en) 2016-07-14
ES2842677T3 (es) 2021-07-14
EP2874639A2 (en) 2015-05-27
EP2858672B1 (en) 2018-04-04
SI2859015T1 (sl) 2018-12-31
EP2874639B1 (en) 2018-03-28
EP2874639A4 (en) 2016-05-11
PT3401402T (pt) 2020-11-11
US9428563B2 (en) 2016-08-30
AU2013271545A1 (en) 2014-10-16
US9156897B2 (en) 2015-10-13
JP6234446B2 (ja) 2017-11-22
CA2869786A1 (en) 2013-12-12
JP6322626B2 (ja) 2018-05-09
US20170044228A1 (en) 2017-02-16
US9359415B2 (en) 2016-06-07
LT2859015T (lt) 2018-07-10
AU2013271541A1 (en) 2014-10-23
PL2859015T3 (pl) 2018-08-31
WO2013184938A3 (en) 2014-01-30
WO2013184938A2 (en) 2013-12-12
AU2013271545C1 (en) 2017-09-28
EP2858672A2 (en) 2015-04-15
AU2013271541C1 (en) 2018-01-18
WO2013184942A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
LT2859015T (lt) Ligandai, modifikuoti cikline permutacija, kaip agonistai ir antagonistai
ZA201503146B (en) Il-6 antagonists and uses thereof
EP2873166A4 (en) GEOFENCING
IL235512A0 (en) New methods
ZA201503067B (en) Anti-pathogenic methods
IL238833A0 (en) Notification of expected location
GB2504569B (en) Needle port
ZA201406204B (en) P-n-p ligand
GB201300194D0 (en) Padlock
AU2012177V (en) Daispanfunk Pandorea jasminoides
TWM432277U (en) Pantyhose structure
GB201218713D0 (en) Improved padlock
AU346813S (en) Swimwear
AU346803S (en) Swimwear
AU346822S (en) Swimwear
AU346811S (en) Swimwear
AU346816S (en) Swimwear
AU344071S (en) Swimwear
AU344081S (en) Swimwear
AU344070S (en) Swimwear
AU344075S (en) Swimwear
AU344067S (en) Swimwear
AU344074S (en) Swimwear
AU344078S (en) Swimwear
AU344079S (en) Swimwear